Anavex Life Sciences Corp (AVXL)

[RedShoulder]

Is there any doubt left that Anavex will be the SOC for Rett; with better results and no diarrhea and vomiting? Not even a contest. Now you additionally know why ACADIA Pharmaceuticals Inc. (ACAD) stock share price and market cap did not improve with the FDA approval.

Anavex will own the entire Rett market, and the Billions in revenues.

From Rett Syndrome Research Trust - Posted on ST by monregi

DAYBUE (TROFINETIDE): KEY FACTS FOR PARENTS

https://reverserett.org/news/articles/daybue-trofinetide-key-facts-for-parents/

KEY SUMMARY FACTS OF LAVENDERTM AND LILAC-1 TRIALS

61% of patients taking DAYBUE did not improve
13% of patients were rated as “much improved”
No data are provided regarding which specific symptoms improve
85% of patients treated with DAYBUE had diarrhea and 29% had vomiting
In the study where everyone received DAYBUE, 46% of patients withdrew before completing the study

The article includes a number of additional data points and trial observations.